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cases were 89%, 89%, and 65%, 43%, respectively (p=0.055). Patterns 
of initial relapse were, local in 11 cases, pleural in 5, nodal in 8, and 
distant in 13. There were 7 Grade 3 pulmonary toxicities (6%), but 
there were no severe adverse effects concerning serial organs. 
Conclusions: Three-DNCCRT for stage I non-small cell lung cancer has 
been safe and effective for not only inoperable but also operable 
cases, and equally effective for peripheral and central tumors, and T1 
and T2 tumors. Our treatment might be an alternative to SBRT 
especially central tumors and T2 tumors, which the results of SBRT 
have not been satisfactory. 
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Purpose/Objective: Locally advanced non-small cell lung cancers 
(NSCLC) are typically treated with 60 to 66 Gy in 2 Gy fractions. Local 
control for this treatment is poor, but it could potentially be improved 
by increasing dose to the more therapy resistant areas,e.g., based on 
the SUV uptake values on the pre-treatment FDG-PET scan. This is the 
dose painting by numbers (DPBN) approach, which intrinsically does 
not allow a conventional PTV margin. This study investigates the 
influence of random and systematic errors on target dose coverage 
with DPBN, in terms of difference between dose to 99% of GTV volume 
(Δ99) when geometric errors are considered. For example, Δ99 = -10 
Gy means that, for 99% of the target volume, the dose delivered is 
decreased by no more than 10 Gy compared to the planned dose. 
Materials and Methods: 9 DPBN plans of stage II/III NSCLC patients 
were considered; a minimum dose of 66 Gy at 2-Gy fractions was 
prescribed to the entire CTV with a boost dose to the high SUV areas 
within the primary GTV, using a non-uniform dose prescription linear 
with the underlying FDG PET SUV. The boost dose was escalated up to 
130 Gy (in 33 fractions) or until the dose limiting constraint of an 
organ at risk was reached. Then, using Monte Carlo methods, a 
probabilistic evaluation of dose endpoints at 90% confidence was 
performed considering 8 different combinations of systematic (Σ) and 
random (σ) geometric uncertainties, taken as standard deviations 
identical in x, y and z as: (Σ,σ) = (5,2); (4,2); (3,2); (2,2); (3,4); (3,3); 
(2,3); and (1,2). 
Results: The impact of geometric errors on the ability to paint dose is 
important, and significant discrepancies of up to 38 Gy occur (Table 
1). 
  
 
The evaluation showed a clear dependence of Δ99 on systematic 
errors (Fig. 1); the influence of random errors was less pronounced. 
The effects of the uncertainties are shifted and smoothed dose peaks; 
indeed the largest differences between planned and delivered dose 
occur where the dose or its gradient are high. 
  
  
Conclusions: A probabilistic evaluation of 9 DPBN plans showed that 
geometric uncertainties should be taken into account before 
approving the plans for treatment, otherwise significant hidden 
discrepancies between prescribed and delivered dose distributions will 
occur. The discrepancies become more acceptable when the 
systematic errors become small (Σ < 2mm), which strongly suggests 
that DPBN should be paired with an accurate IGRT. Probabilistic 
optimization, taking uncertainties into account also at the planning 
stage, might intrinsically mitigate the reported issues. 
